Commercial markups on pediatric oncology drugs at 340B pediatric hospitals
Ian T. T. Liu,
Junyi Wang,
Ameet Sarpatwari
et al.
Abstract:Eligible pediatric hospitals can purchase clinician‐administered drugs at discounted rates through the 340B Drug Pricing Program and charge payers prices exceeding drug acquisition costs, but the magnitude of these markups is not known. In a study of newly approved oncology drugs at pediatric 340B hospitals, median negotiated prices ranged from 102% (interquartile range [IQR]: 91%–156%) of average sales price (ASP) at Phoenix Children's Hospital to 630% (IQR: 526%–630%) at Driscoll Children's Hospital. Pediatr… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.